SEC Comment Letter for Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Apr 15, 2020
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: April 15, 2020 · CIK: 0001649989 · Accession: 0000000000-20-003262
AI Filing Summary & Sentiment
File numbers found in text: 333-237607
Letter
April 15, 2020 Lawrence A. Kenyon President, Chief Executive Officer and Chief Financial Officer Outlook Therapeutics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512 Re:Outlook Therapeutics, Inc. Registration Statement on Form S-1 Filed April 8, 2020 File No. 333-237607 Dear Mr. Kenyon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marianne C. Sarrazin
Show Raw Text
April 15, 2020
Lawrence A. Kenyon
President, Chief Executive Officer and Chief Financial Officer
Outlook Therapeutics, Inc.
7 Clarke Drive
Cranbury, New Jersey 08512
Re:Outlook Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 8, 2020
File No. 333-237607
Dear Mr. Kenyon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Marianne C. Sarrazin